Urinary β‐HCG in Benign and Malignant Urinary Tract Diseases

• Published in: Disease markers 1994-01, Vol.12 (2), p.109-115
• Main Authors: Halim, A.-B., Barakat, M., El-Zayat, A. M., Daw, M., El-Ahmady, O.
• Format: Article
• Language: English
• ISSN: 0278-0240; 1875-8630
• DOI: 10.1155/1994/179287

Detectable leve ls of HCG have been reported in conditions other th an normal pregnancy, including threatened abortion, ectopic pregnancy, trophoblastic tumors, carcinomas of the stomach, liver, pancreas and breast as well as multiple myeloma and melanoma. The present study was conducted to estimate urinary β‐HCG in bladder cancer and benign urinary tract disorders. 163 individuals were included, 68 with bladder cancer (60 males and 8 females), 64 with benign urinary tract diseases (55 males and 9 females) and 31 normal healthy controls (26 males and 5 females). Urinary β‐HCG was estimated by the ELISA technique using the reagents supplied by DRG International Inc., Germany. Results of th e study revealed an overexpression of β‐HCG in mali gnant and benign urinary tract diseases. 60.3% of the cancer patients and 29.7% of patients with benign diseases showed urinary β‐HCG values above the upper limit of the control group (2mIU/ml ).